All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

LYVE1 Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA949150A0HU
Size US$210
Order now
Image
  • Immunofluorescence staining of HepG2 with CSB-RA949150A0HU at 1:25, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 505-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
  • Overlay Peak curve showing HepG2 cells surface stained with CSB-RA949150A0HU (red line) at 1:50. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1µg/1*106cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was rabbit IgG (1µg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Q9Y5Y7
Target Names
LYVE1
Alternative Names
Lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE-1) (Cell surface retention sequence-binding protein 1) (CRSBP-1) (Extracellular link domain-containing protein 1) (Hyaluronic acid receptor), LYVE1, CRSBP1 HAR XLKD1
Species Reactivity
Human
Immunogen
A synthesized peptide derived from Human LYVE1
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
11C11
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, IF, FC
Recommended Dilution
Application Recommended Dilution
IF 1:50-1:200
FC 1:50-1:200
Protocols
ELISA Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

LYVE1, the lymphatic vessel endothelial hyaluronic acid receptor 1, serves as a critical marker for lymphatic endothelial cells and plays an essential role in hyaluronan transport and lymphatic vessel function. This receptor has become indispensable in cardiovascular research, particularly for studies investigating lymphangiogenesis, tumor metastasis via lymphatic routes, and inflammatory processes where lymphatic drainage is implicated.

This recombinant monoclonal antibody, clone 11C11, offers the reproducibility that demanding experimental workflows require. Generated through recombinant technology with a defined sequence, it eliminates the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations. The rabbit IgG format, raised against a synthetic peptide derived from human LYVE1, provides consistent performance across experiments while the affinity-chromatography purification ensures high specificity for your target.

Validation studies demonstrate reliable performance in both immunofluorescence and flow cytometry applications using HepG2 cells. Immunofluorescence staining at 1:25 dilution with DAPI counterstaining reveals clear signal localization, while flow cytometry analysis at 1:50 dilution shows distinct positive population separation compared to isotype controls, confirming specific detection of LYVE1-expressing cells. These validated protocols provide flexibility whether you need spatial information from imaging approaches or quantitative population analysis through flow cytometry. ELISA compatibility further extends the antibody's utility for biochemical quantification studies.

For researchers investigating lymphatic biology, vascular development, or the role of lymphatic vessels in disease progression, this antibody delivers the technical consistency needed to generate reliable, publishable data in human-focused studies.

Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

LYVE1 Antibodies

LYVE1 Proteins

LYVE1 ELISA kits

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes.
Gene References into Functions
  1. LYVE1 was up-regulated in the malignant Middle Cerebral Artery Infarction. PMID: 28828208
  2. this study shows up-regulation of LYVE-1 expression in the fetal circulation of conducting and exchange villi of HIV-infected pre-eclamptics PMID: 27529307
  3. Dendritic cells (DCs) docked to the basolateral surface of lymphatic vessels and transited to the lumen through hyaluronan-mediated interactions with the lymph-specific endothelial receptor LYVE-1. Targeted deletion of the gene Lyve1, antibody blockade or depletion of the DC hyaluronan coat not only delayed lymphatic trafficking of dermal DCs but also blunted their capacity to prime CD8(+) T cell responses in LNs. PMID: 28504698
  4. These findings reveal binding is dependent not just on clustering but also on the biochemical properties of LYVE-1 homodimers. They also mark LYVE-1 as the first Link protein superfamily member requiring covalent homodimerization for function and suggest the interchain disulfide acts as a redox switch in vivo. PMID: 27733683
  5. LYVE1 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
  6. Immunostaining analyses in psoriasis skin lesions suggested that the ectodomain shedding of LYVE-1 occurred in lymphatic vessels undergoing chronic inflammation. These results indicate that the ectodomain shedding of LYVE-1 might be involved in promoting pathological lymphangiogenesis. PMID: 26966180
  7. These results demonstrate the prerequisite of a critical LYVE-1 threshold density and show that hyaluronan binding may be elicited in lymphatic endothelium by surface clustering with divalent LYVE-1 mAbs. PMID: 26823460
  8. We have established a novel, three-protein biomarker panel that is able to detect patients with early-stage pancreatic cancer in urine specimens:LYVE-1, REG1A, and TFF1 were selected as candidate biomarkers PMID: 26240291
  9. Data (including data from studies in knockout mice) suggest LYVE1 mediates adhesion of group A Streptococci (GAS) to lymphatic vesicular endothelium via capsular hyaluronan; this appears to be critical factor for lymphatic trafficking of GAS in vivo. PMID: 26352587
  10. High expression of LYVE-1 is associated with atherosclerotic arteries. PMID: 25318003
  11. High LYVE expression is associated with visceral pleural invasion and lymphatic thromboembolism in non-small-cell lung cancer. PMID: 25141859
  12. Data indicate that detection of lymphatic vascular invasion (LVI) can be optimized by specific D2-40 or LYVE-1 staining. PMID: 21974896
  13. High-low cell surface HA content of tumor cells through the interaction with LYVE-1 leads to adhesion differences. PMID: 23717428
  14. FGF2 binds to LYVE-1 with a higher affinity than any other known LYVE-1-binding molecules, such as hyaluronan or PDGF-BB. Glycosylation of LYVE-1 is important for FGF2 binding. PMID: 23264596
  15. CRSBP-1-associated fibrillar structures are identical to the ER network as evidenced by the co-localization of CRSBP-1 and BiP in these cells PMID: 22673514
  16. LYVE-1 may have value as predictor of outcome in neuroblastoma PMID: 22241180
  17. Significant correlation between LYVE-1 and Prox-1 expression was observed in non-small cell lung cancer. Expression was also correlated with lymph node metastasis. PMID: 21500548
  18. LYVE-1, VEGFR-3 and CD44 all play an important role in lymphangiogenesis, invasion and metastasis PMID: 21912471
  19. these data support interdependent roles for emmprin, LYVE-1 and BCRP in chemotherapeutic resistance for PEL PMID: 21660043
  20. Results suggest that LYVE-1 allows the adhesion of tumor cells through the interaction of HA on the tumor cell membrane with LYVE-1. PMID: 21291635
  21. Intratumoral lymph vessel density marked by LYVE-1 in laryngeal carcinoma was significantly correlated with tumor infiltration and metastasis. PMID: 17144490
  22. Data show that the density of LYVE-1/+ capillaries in skeletal muscle was observed to decrease significantly over the time course of the exercise intervention. PMID: 20863269
  23. findings indicated that LYVE-1 attenuation in sinusoidal endothelium was one of the manifestations of capillarization, and was associated with hepatic disease progression PMID: 19908110
  24. LYVE-1 indicates an increase of lymphangiogenesis in colorectal carcinoma. PMID: 19742347
  25. A study using specific markers of endothelium (CD31) and lymphatic endothelial cells (Lyve-1, Podoplanin) shows that not only angiogenesis but also lymphangiogenesis occurs within the nodule. PMID: 20011036
  26. new approach measuring lymphangiogenesis using LYVE-1, a novel, specific lymphatic marker in breast cancer tissue PMID: 11689016
  27. LYVE-1 is not exclusive to the lymph vessels PMID: 11719431
  28. LYVE-1 does not seem to be a reliable marker for proliferating infantile hemangiomas. PMID: 16424896
  29. findings indicate (1) the importance of LYVE-1, but not CD44, in regulation of HA metabolism in the maternal-fetal interface and fetal circulation, and (2) possible dual blood and lymphatic phenotypic characteristics in fetal endothelium PMID: 16569201
  30. Molecular data based on gene transcriptional profiles of a 3-gene set (GPC3, LYVE1, and survivin) allow a reliable diagnosis of early hepatocellular carcinoma. PMID: 17087938
  31. analysis of inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1 PMID: 17884820
  32. DC-sign+ CD163+ macrophages expressing hyaluronan receptor LYVE-1 are located within chorion villi of the placenta. PMID: 18078989
  33. Presence of LYVE-1 in pancreatic islets and in some pancreatic endocrine tumors may suggest structure-function relationship of LYVE-1/lymphatic vessel in hormone synthesis and secretion. PMID: 18090227
  34. LYVE-1 immunohistochemistry appeared to be a useful method for detecting lymphatics invaded by cancer cells, and detailed examination of the submucosa around the tumor may be important for predicting LN metastasis. PMID: 18181096
  35. LYVE-1 expression and the lymphatic density of the muscularis propria are significantly greater than those of other layers of urothelium, including the epithelium, lamina propria, perivesical fat, and serosa PMID: 18342921
  36. LYVE-1 is expressed in a reticulum cell neoplasm in an axillary lymph node. This reticulum cell sarcoma is a lymphatic sinus lining cell sarcoma which might represent another subtype of reticulum cell sarcomas. PMID: 18386053
  37. The normal adult human choroid does not contain typical lymph vessels, but is endowed with a significant number of LYVE-1 positive macrophages. PMID: 18689706
  38. complexity in the regulation of LYVE-1 function and raise the possibility that this receptor, like CD44, may become active after appropriate unmasking in vivo. PMID: 19033446
  39. LYVE-1 immunostaining in some gastrointestinal carcinoids may support a structure-function relationship of lymphatic vessels/hyaluronan receptor for modulating synthesis and secretion of hormones and amines by carcinoid tumour cells. PMID: 19291537
  40. CRSBP-1 exhibits dual ligand (CRS-containing growth regulators (v-sis gene product and insulin-like growth factor binding protein-3, IGFBP-3) and hyaluronic acid) binding activity and plays a role in autocrine regulation of cell growth. PMID: 12912978

Show More

Hide All

Subcellular Location
Membrane; Single-pass type I membrane protein. Note=Localized to the plasma membrane and in vesicles near extranuclear membranes which may represent trans-Golgi network (TGN) and endosomes/prelysosomeal compartments. Undergoes ligand-dependent internalization and recycling at the cell surface.
Tissue Specificity
Mainly expressed in endothelial cells lining lymphatic vessels.
Database Links

HGNC: 14687

OMIM: 605702

KEGG: hsa:10894

STRING: 9606.ENSP00000256178

UniGene: Hs.655332

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?
Related pathways
Target Therapy
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
No. 269, Shendun 5th Road, Donghu Hi-Tech Development Area, Hubei Province, 430206, P.R.China
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*